Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 PEP10.4 | DOI: 10.1530/endoabs.73.PEP10.4

ECE2021 Presented Eposters Presented ePosters 10: Thyroid (8 abstracts)

Efficacy of a combined administration of myo-inositol and vitamin D in patients with autoimmune thyroiditis

Ivan Pankiv , Nataliia Pashkovska , Galina Koval , Antonina Piddubna , Yuliya Marchuk , Nataliia Abramova & Iryna Tsaryk


Bukovinian State Medical University, Clinical Immunology, Allergology and Endocrinology, Chernivtsi, Ukraine


Background and aim

Autoimmune thyroiditis (AIT) is one of the most common autoimmune diseases, affecting more than 10% of females and 2% of males in the overall population. Clinical evidence suggests that oral supplementation with myo-inositol (MI) and vitamin D (VD) is useful in the treatment of AIT. MI is a carbocyclic polyol precursor of phosphoinositide synthesis. It is involved in cell signaling and, precisely, as a second messenger regulating the activities of Thyroid Stimulating Hormone (TSH). The aim of this study was to investigate the efficacy of a combined administration of MI and VD in patients with AIT.

Patients and methods

74 outpatients (mean age 42.39 ± 8.2 years) with AIT were enrolled in this prospective randomized controlled trial from May to September 2019. A total of 74 patients with AIT having TSH levels between 4.0 and 6.0 µIU/ml, elevated serum thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (Tg-Ab), normal free thyroxine (fT4) and free triiodothyronine (fT3) levels were randomized into 2 groups: one receiving MI-VD and the other one VD alone. To provide additional information concerning thyroid tissue texture, high-resolution ultrasound scan of the thyroidal area was carried out.

Results

A significant decrease in serum TSH levels was noted in patients of group MI-VD compared prior and after treatment (P < 0.05), showing at baseline 5.18 ± 0.52 µIU/ml and 3.06 ± 0.48 µIU/ml over 6 months treatment. The decrement in control group before vs. post-treatment was not significant (4.93 ± 0.82 µIU/ml and 4.16 ± 0.81 µIU/ml). TSH, thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (Tg-Ab) levels were significantly decreased in patients treated with combined MI-VD after six months of treatment. Also, a significant free serum thyroxine (fT4) increase was observed in MI-VD group. In both groups at baseline plasma VD levels were not different (19.4 ± 3.7 ng/ml group MI-VD; 18.9 ± 2.8 ng/ml group VD). After 6 months treatment, VD values were significantly augmented in each group compared to baseline.

Conclusions

The administration of MI-VD is significantly effective in decreasing TSH, TPO-Ab and Tg-Ab levels. Such treatment restored euthyroidism in patients diagnosed with AIT.

Keywords

Autoimmune thyroiditis, Myo-inositol, Vitamin D.

Volume 73

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.